These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38357851)

  • 1. Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin-Related Parkinson's Disease.
    Papagiannakis N; Liu H; Koros C; Simitsi AM; Stamelou M; Maniati M; Buena-Atienza E; Kartanou C; Karadima G; Makrythanasis P; Vatsellas G; Valente EM; Gasser T; Stefanis L
    Mov Disord; 2024 Apr; 39(4):715-722. PubMed ID: 38357851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterozygous PRKN mutations are common but do not increase the risk of Parkinson's disease.
    Zhu W; Huang X; Yoon E; Bandres-Ciga S; Blauwendraat C; Billingsley KJ; Cade JH; Wu BP; Williams VH; Schindler AB; Brooks J; Gibbs JR; Hernandez DG; Ehrlich D; Singleton AB; Narendra DP
    Brain; 2022 Jun; 145(6):2077-2091. PubMed ID: 35640906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson's Disease.
    Yu E; Rudakou U; Krohn L; Mufti K; Ruskey JA; Asayesh F; Estiar MA; Spiegelman D; Surface M; Fahn S; Waters CH; Greenbaum L; Espay AJ; Dauvilliers Y; Dupré N; Rouleau GA; Hassin-Baer S; Fon EA; Alcalay RN; Gan-Or Z
    Mov Disord; 2021 Jan; 36(1):178-187. PubMed ID: 32970363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
    Daida K; Funayama M; Billingsley KJ; Malik L; Miano-Burkhardt A; Leonard HL; Makarious MB; Iwaki H; Ding J; Gibbs JR; Ishiguro M; Yoshino H; Ogaki K; Oyama G; Nishioka K; Nonaka R; Akamatsu W; Blauwendraat C; Hattori N
    Mov Disord; 2023 Dec; 38(12):2249-2257. PubMed ID: 37926948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the relationship between monoallelic PRKN mutations and Parkinson's risk.
    Lubbe SJ; Bustos BI; Hu J; Krainc D; Joseph T; Hehir J; Tan M; Zhang W; Escott-Price V; Williams NM; Blauwendraat C; Singleton AB; Morris HR;
    Hum Mol Genet; 2021 Mar; 30(1):78-86. PubMed ID: 33448283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification & characterization of leucine-rich repeat kinase 2 & parkin RBR E3 ubiquitin protein ligase variants in patients with Parkinson's disease.
    Halder T; Verma SP; Raj J; Pandey S; Singh RK; Sharma V; Joshi D; Das P
    Indian J Med Res; 2020 Nov; 152(5):498-507. PubMed ID: 33707392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations.
    González-Casacuberta I; Morén C; Juárez-Flores DL; Esteve-Codina A; Sierra C; Catalán-García M; Guitart-Mampel M; Tobías E; Milisenda JC; Pont-Sunyer C; Martí MJ; Cardellach F; Tolosa E; Artuch R; Ezquerra M; Fernández-Santiago R; Garrabou G
    Neurobiol Aging; 2018 May; 65():206-216. PubMed ID: 29501959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRKN-linked familial Parkinson's disease: cellular and molecular mechanisms of disease-linked variants.
    Clausen L; Okarmus J; Voutsinos V; Meyer M; Lindorff-Larsen K; Hartmann-Petersen R
    Cell Mol Life Sci; 2024 May; 81(1):223. PubMed ID: 38767677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism.
    Borsche M; König IR; Delcambre S; Petrucci S; Balck A; Brüggemann N; Zimprich A; Wasner K; Pereira SL; Avenali M; Deuschle C; Badanjak K; Ghelfi J; Gasser T; Kasten M; Rosenstiel P; Lohmann K; Brockmann K; Valente EM; Youle RJ; Grünewald A; Klein C
    Brain; 2020 Oct; 143(10):3041-3051. PubMed ID: 33029617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial DNA heteroplasmy distinguishes disease manifestation in PINK1/PRKN-linked Parkinson's disease.
    Trinh J; Hicks AA; König IR; Delcambre S; Lüth T; Schaake S; Wasner K; Ghelfi J; Borsche M; Vilariño-Güell C; Hentati F; Germer EL; Bauer P; Takanashi M; Kostić V; Lang AE; Brüggemann N; Pramstaller PP; Pichler I; Rajput A; Hattori N; Farrer MJ; Lohmann K; Weissensteiner H; May P; Klein C; Grünewald A
    Brain; 2023 Jul; 146(7):2753-2765. PubMed ID: 36478228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of induced pluripotent stem cells (NIMHi015-A) from a Parkinson's Disease patient harbouring a homozygous Exon 3 deletion in the PRKN gene.
    Banerjee R; Ghanty R; Jagtap S; Holla V; Kamble N; Yadav R; Pal PK; Datta I
    Stem Cell Res; 2024 Jun; 77():103440. PubMed ID: 38739971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare and novel variants of PRKN and PINK1 genes in Vietnamese patients with early-onset Parkinson's disease.
    Ton ND; Thuan ND; Thuong MTH; Ngoc TTB; Nhung VP; Hoa NTT; Nam NH; Dung HT; Son ND; Ba NV; Bac ND; Tai TN; Dung LTK; Hung NT; Duong NT; Ha NH; Hai NV
    Mol Genet Genomic Med; 2020 Oct; 8(10):e1463. PubMed ID: 32856414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the canvas of PRKN mutations in familial and early-onset Parkinson disease.
    Pandey S; Tomar LR; Kumar S; Dinesh S; Thelma BK
    Parkinsonism Relat Disord; 2019 Sep; 66():216-219. PubMed ID: 31409571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations.
    Deng H; Le WD; Hunter CB; Ondo WG; Guo Y; Xie WJ; Jankovic J
    Arch Neurol; 2006 Feb; 63(2):273-7. PubMed ID: 16476817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRKN, DJ-1, and PINK1 screening identifies novel splice site mutation in PRKN and two novel DJ-1 mutations.
    Ghazavi F; Fazlali Z; Banihosseini SS; Hosseini SR; Kazemi MH; Shojaee S; Parsa K; Sadeghi H; Sina F; Rohani M; Shahidi GA; Ghaemi N; Ronaghi M; Elahi E
    Mov Disord; 2011 Jan; 26(1):80-9. PubMed ID: 21322020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial and autophagic alterations in skin fibroblasts from Parkinson disease patients with Parkin mutations.
    González-Casacuberta I; Juárez-Flores DL; Ezquerra M; Fucho R; Catalán-García M; Guitart-Mampel M; Tobías E; García-Ruiz C; Fernández-Checa JC; Tolosa E; Martí MJ; Grau JM; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
    Aging (Albany NY); 2019 Jun; 11(11):3750-3767. PubMed ID: 31180333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease.
    Isonaka R; Goldstein DS; Zhu W; Yoon E; Ehrlich D; Schindler AB; Kokkinis AD; Sabir MS; Scholz SW; Bandres-Ciga S; Blauwendraat C; Gonzalez-Alegre P; Lopez G; Sidransky E; Narendra DP
    Mov Disord; 2021 Oct; 36(10):2346-2357. PubMed ID: 34076298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-occurrence of PRKN and SYNJ1 variants in Early-Onset Parkinson's disease.
    Cotrin JC; Piergiorge RM; Gonçalves AP; Pereira JS; Gerber AL; de Campos Guimarães AP; de Vasconcelos ATR; Santos-Rebouças CB
    Metab Brain Dis; 2024 Jun; 39(5):915-928. PubMed ID: 38836947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondria-Endoplasmic Reticulum Contact Sites Dynamics and Calcium Homeostasis Are Differentially Disrupted in PINK1-PD or PRKN-PD Neurons.
    Grossmann D; Malburg N; Glaß H; Weeren V; Sondermann V; Pfeiffer JF; Petters J; Lukas J; Seibler P; Klein C; Grünewald A; Hermann A
    Mov Disord; 2023 Oct; 38(10):1822-1836. PubMed ID: 37449534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and characterization of induced pluripotent stem cell (iPSC) lines of two asymptomatic individuals carrying a heterozygous exon 7 deletion in Parkin (PRKN) and two non-carriers from the same family.
    Castelo Rueda MP; Gilmozzi V; Riekschnitz DA; Di Segni M; Silipigni R; Pramstaller PP; Hicks AA; Pichler I; Zanon A
    Stem Cell Res; 2022 Apr; 60():102692. PubMed ID: 35121197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.